Company overview
Basic information
Company name
Nb kadras, MB
Company code
306998950
VAT code
LT100017890719
Registered address
Ukmergė, A. Smetonos g. 45, LT-20129
Registration date
2024-09-25
Company age: 2 y. 1 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Not disclosed
(personal)
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Photographic activities
Ownership form
Private without foreign capital
MB Nb kadras
Company code: 306998950
Address: Ukmergė, A. Smetonos g. 45, LT-20129
VAT code: LT100017890719
Description
This description was generated by artificial intelligence.
Nb kadras, MB (company code 306998950) is a private small partnership registered on 2024-09-25 and currently operational. It is classified as a micro-sized national private non-financial company with private ownership, where Lithuanian natural and legal persons hold more than 50% of the authorised capital and there is no foreign investor capital. Governance is listed as CEO only. The company operates in Ukmerge, at A. Smetonos g. 45, LT-20129, in Ukmerges district municipality, Vilnius County. Its main activity is EVRK code N.74.20.00, Photographic activities. Financially, the company reported revenue of EUR 20.5K in 2025, up sharply from EUR 1.6K in 2024, when the first reporting period covered 97 days. Net profit was EUR 410 in 2025, compared with EUR 16 in 2024, and the profit margin was 2.0%. At the end of 2025, total assets stood at EUR 26.2K, including EUR 20.4K in long-term assets and EUR 5.8K in short-term assets. Liabilities were EUR 6.9K and equity EUR 456. Staff metrics are recorded for 2026, so far in 2026, but no average employee or wage figures are shown in the provided data.
Download a detailed company report
Make confident decisions with all the information about Nb kadras, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.